

Tafolecimab

| | |
|-----------|---|
| Cat. No.: | HY-P99552 |
| CAS No.: | 2225109-03-3 |
| Target: | PCSK9 |
| Pathway: | Metabolic Enzyme/Protease |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |

BIOLOGICAL ACTIVITY

Description

Tafolecimab (IBI-306) is a human IgG2 monoclonal antibody that specifically binds PCSK-9 and reduces LDL-C levels by inhibiting PCSK-9-mediated endocytosis of the LDL receptor, which in turn enhances clearance of LDL-C and leads to a reduction in LDL-C levels. Tafolecimab may be used in studies of hypercholesterolaemia^[1].

REFERENCES

[1]. Y Cui, et al. Tafolecimab, a novel potential long-acting PCSK9 monoclonal antibody: efficacy and safety in healthy and hypercholesterolemia subjects. *European Heart Journal*, Volume 41, Issue Supplement_2, November 2020.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA